AstraZeneca is abandoning a play for the inflammatory bowel disease market. After seeing clinical trial timelines spiral, the Anglo-Swedish drugmaker has stopped development of a would-be rival to products sold by AbbVie and Johnson & Johnson.
[Fierce Biotech]
